These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39055420)

  • 21. [Hypotensive effect of three different formulations of brimonidine tartrate in normal eyes].
    Abud TB; Scuoteguazza Filho M; Oliveira ES; Abud JF; Prata Junior JA
    Arq Bras Oftalmol; 2013; 76(2):69-71. PubMed ID: 23828464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.
    Cantor LB
    Expert Opin Pharmacother; 2000 May; 1(4):815-34. PubMed ID: 11249518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brimonidine.
    Cantor LB; Burke J
    Expert Opin Investig Drugs; 1997 Aug; 6(8):1063-83. PubMed ID: 15989664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension.
    Fan S; Agrawal A; Gulati V; Neely DG; Toris CB
    J Glaucoma; 2014; 23(5):276-81. PubMed ID: 24886701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of brimonidine tartrate on ocular hemodynamic measurements.
    Lachkar Y; Migdal C; Dhanjil S
    Arch Ophthalmol; 1998 Dec; 116(12):1591-4. PubMed ID: 9869786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
    Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
    J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute and chronic effects of brimonidine 0.2% on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study.
    Vetrugno M; Maino A; Cantatore F; Ruggeri G; Cardia L
    Clin Ther; 2001 Sep; 23(9):1519-28. PubMed ID: 11589264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes.
    Von Zup M; Lassaline M; Kass PH; Miller PE; Thomasy SM
    Equine Vet J; 2017 Nov; 49(6):810-814. PubMed ID: 28470857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma].
    Heimann K; Peschgens T; Merz U; Hoernchen H; Wenzl T
    Ophthalmologe; 2007 Jun; 104(6):505-7. PubMed ID: 17334744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preservative-free
    Duru Z; Ozsaygili C
    Cutan Ocul Toxicol; 2020 Mar; 39(1):21-24. PubMed ID: 31615279
    [No Abstract]   [Full Text] [Related]  

  • 33. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
    Frampton JE
    Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification.
    Katsimpris JM; Siganos D; Konstas AG; Kozobolis V; Georgiadis N
    J Cataract Refract Surg; 2003 Dec; 29(12):2288-94. PubMed ID: 14709288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of objective ocular redness measured with Keratograph 5M in glaucoma patients after instilling brimonidine drops.
    Montolío-Marzo E; Fernández-Narros R; Morales-Fernández L; García-Bella J; Sáenz-Francés F; García-Feijoo J; Martínez-de-la-Casa JM
    Eur J Ophthalmol; 2024 Mar; 34(2):480-486. PubMed ID: 37661653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
    Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
    J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness.
    Torkildsen GL; Sanfilippo CM; DeCory HH; Gomes PJ
    Curr Eye Res; 2018 Jan; 43(1):43-51. PubMed ID: 29120262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
    Maus TL; Nau C; Brubaker RF
    Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(3):113-120. PubMed ID: 31393455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.